Heat shock protein 70 (Hsp70) peptide activated Natural Killer (NK) cells for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCTx) - From preclinical studies to a clinical phase II trial

Frontiers in Immunology

Volumn 6, Issue MAR, 2015, Pages

  Specht, Hanno M ^a   Ahrens, Norbert ^b   Blankenstein, Christiane ^a   Duell, Thomas ^c   Fietkau, Rainer ^d   Gaipl, Udo S ^d   Günther, Christine ^e   Gunther, Sophie ^a   Habl, Gregor ^a   Hautmann, Hubert ^a   Hautmann, Matthias ^b   Huber, Rudolf M ^f   Molls, Michael ^a   Offner, Robert ^b   Rödel, Claus ^g   Rödel, Franz ^g   Schuetz, Martin ^h   Combs, Stephanie E ^a   Multhoff, Gabriele ^a,i  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c Thoracic Oncology Asklepios Lungenfachkliniken   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e Apceth GmbH and Co KG   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^h KLINIKUM BOGENHAUSEN   (Germany)

ⁱ INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD94 ANTIGEN; GRANZYME B; HEAT SHOCK PROTEIN 70; INTERLEUKIN 2;

APOPTOSIS; BRONCHOSCOPY; CANCER IMMUNOTHERAPY; CELL DENSITY; CELL THERAPY; CHEMORADIOTHERAPY; COLORECTAL CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; TUMOR BIOPSY;

EID: 84926683486     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00162     Document Type: Review

References (36)

1. Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science (2002) 295:1852-8.
2. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones (2005) 10:86-103.
3. Murphy ME. The HSP70 family and cancer. Carcinogenesis (2013) 34:1181-8. doi:10.1093/carcin/bgt111.
4. Boroughs LK, Antonyak MA, Johnson JL, Cerione RA. A unique role for heat shock protein 70 and its binding partner tissue transglutaminase in cancer cell migration. J Biol Chem (2011) 286:37094-107. doi: 10.1074/jbc.M111.242438.
5. Ciocca DR, Arrigo AP, Calderwood SK. Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update. Archives of Toxicology (2013) 87:19-48. doi:10.1007/s00204-012-0918-z.
6. Gabai VL, Budagova KR, Sherman MY. Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents. Oncogene (2005) 24:3328-38.
7. Teng Y, Ngoka L, Mei Y, Lesoon L, Cowell JK. HSP90 and HSP70 proteins are essential for stabilization and activation of WASF3 metastasis-promoting protein. J Biol Chem (2012) 287:10051-9. doi:10.1074/jbc.M111.335000.
8. Jäättelä M. Heat shock proteins as cellular lifeguards. Ann Med (1999) 31:261-71.
9. Jäättelä M, Wissing D, Kokholm K, Kallunki T, Egeblad M. Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. EMBO J (1998) 17:6124-34.
10. Multhoff G, Botzler C, Wiesnet M, Muller E, Meier T, Wilmanns W, et al. A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer (1995) 61:272-9.
11. Shin BK, Wang H, Yim AM, Le Naour F, Brichory F, Jang JH, et al. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem (2003) 278:7607-16.
12. Stangl S, Gehrmann M, Riegger J, Kuhs K, Riederer I, Sievert W, et al. Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proc Natl Acad Sci USA (2011) 108:733-8. doi:10.1073/pnas.1016065108.
13. Gehrmann M, Schmetzer H, Eissner G, Haferlach T, Hiddemann W, Multhoff G. Membrane-bound heat shock protein 70 (Hsp70) in acute myeloid leukemia: a tumor specific recognition structure for the cytolytic activity of autologous NK cells. Haematologica (2003) 88:474-6.
14. Multhoff G, Botzler C, Jennen L, Schmidt J, Ellwart J, Issels R. Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J Immunol (1997) 158:4341-50.
15. Stangl S, Wortmann A, Guertler U, Multhoff G. Control of metastasized pancreatic carcinomas in SCID/beige mice with human IL-2/TKD-activated NK cells. J Immunol (2006) 176:6270-6.
16. Pfister K, Radons J, Busch R, Tidball JG, Pfeifer M, Freitag L, et al. Patient survival by Hsp70 membrane phenotype: association with different routes of metastasis. Cancer (2007) 110:926-35.
17. Hightower LE, Guidon PT, Jr. Selective release from cultured mammalian cells of heat-shock (stress) proteins that resemble glia-axon transfer proteins. J Cell Physiol (1989) 138:257-66.
18. Gehrmann M, Liebisch G, Schmitz G, Anderson R, Steinem C, De MA, et al. Tumor-specific Hsp70 plasma membrane localization is enabled by the glycosphingolipid Gb3. PLoS One (2008) 3:e1925. doi:10.1371/journal.pone.0001925.
19. Gehrmann M, Marienhagen J, Eichholtz-Wirth H, Fritz E, Ellwart J, Jaattela M, et al. Dual function of membrane-bound heat shock protein 70 (Hsp70), Bag-4, and Hsp40: protection against radiation-induced effects and target structure for natural killer cells. Cell Death Differ (2005) 12:38-51.
20. Gehrmann M, Schönberger J, Zilch T, Rossbacher L, Thonigs G, Eilles C, et al. Retinoid-and sodium-butyrate-induced decrease in heat shock protein 70 membrane-positive tumor cells is associated with reduced sensitivity to natural killer cell lysis, growth delay, and altered growth morphology. Cell Stress Chaperones (2005) 10:136-46.
21. Gehrmann M, Radons J, Molls M, Multhoff G. The therapeutic implications of clinically applied modifiers of heat shock protein 70 (Hsp70) expression by tumor cells. Cell Stress Chaperones (2008) 13:1-10. doi:10.1007/s12192-007-0006-0.
22. Schilling D, Gehrmann M, Steinem C, De MA, Pockley AG, Abend M, et al. Binding of heat shock protein 70 to extracellular phosphatidylserine promotes killing of normoxic and hypoxic tumor cells. FASEB J (2009) 23:2467-77. doi:10.1096/fj.08-125229.
23. Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA, et al. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer (NK) cells. Cancer Res (2005) 65:5238-47.
24. Multhoff G, Pfister K, Gehrmann M, Hantschel M, Gross C, Hafner M, et al. A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity. Cell Stress Chaperones (2001) 6:337-44.
25. Gross C, Schmidt-Wolf IG, Nagaraj S, Gastpar R, Ellwart J, Kunz-Schughart LA, et al. Heat shock protein 70-reactivity is associated with increased cell surface density of CD94/CD56 on primary natural killer cells. Cell Stress Chaperones (2003) 8:348-60.
26. Gross C, Hansch D, Gastpar R, Multhoff G. Interaction of heat shock protein 70 peptide with NK cells involves the NK receptor CD94. J Biol Chem (2003) 384:267-79.
27. Gross C, Koelch W, DeMaio A, Arispe N, Multhoff G. Cell surface-bound heat shock protein 70 (Hsp70) mediates perforin-independent apoptosis by specific binding and uptake of granzyme B. J Biol Chem (2003) 278:41173-81.
28. Moser C, Schmidbauer C, Gurtler U, Gross C, Gehrmann M, Thonigs G, et al. Inhibition of tumor growth in mice with severe combined immunodeficiency is mediated by heat shock protein 70 (Hsp70)-peptide-activated, CD94 positive natural killer cells. Cell Stress Chaperones (2002) 7:365-73.
29. Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, et al. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase I trial. Clin Cancer Res (2004) 10:3699-707.
30. Garrido P, Rosell R, Arellano A, Andreu F, Domine M, Perez-Casas A, et al. Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study. Lung Cancer (2013) 81:84-90. doi:10.1016/j.lungcan.2013.03.009.
31. Huber RM, Engel-Riedel W, Kollmeier J, Andreas S, Staar S, Klautke G, et al. GILT study: Oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): Final results of a phase III study. ASCO Univ (2012):abstr 7001.
32. Machtay M, Duan F, Siegel BA, Snyder BS, Gorelick JJ, Reddin JS, et al. Prediction of survival by [18F]-fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol (2013) 31:3823-30. doi:10.1200/JCO.2012.47.5947.
33. Breuninger S, Erl J, Knape C, Gunther S, Regel Y, Rödel F, et al. Quantitative analysis of liposomal heat shock protein 70 (Hsp70) in the blood of tumor patients using a novel lipHsp70 ELISA. Clin Cellular Immunol (2014) 30:237-46. doi:104172/2155-9899.1000264.
34. Gehrmann M, Specht HM, Bayer C, Brandstetter M, Chizzali B, Duma M, et al. Hsp70-a biomarker for tumor detection and monitoring of outcome radiation therapy with squamous cell carcinoma of the head and neck. Rad Oncol (2014) 9:131. doi:10.1186/1748-717X-9-131.
35. Shevtsov MA, Pozdnyakov AV, Mikhrina AL, Yakovleva LY, Nikolaev BP, Dobrodumov AV, et al. Effective immunotherapy of rat glioblastoma with prolonged intratumoral delivery of exogenous heat shock protein 70 (Hsp70). Int J Cancer (2014) 135:2118-28. doi:10.1002/ijc.28858.
36. Milani V, Stangl S, Issels R, Gehrmann M, Wagner B, Hube K, et al. Antitumor activity of patient-derived NK cells after cell-based immunotherapy-a case report. J Transl Med (2009) 7:50. doi:10.1186/1479-5876-7-50.